These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 23543660

  • 1. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
    Cohen A, Stein EM, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, McMahon DJ, Nickolas TL, Müller R, Zwahlen A, Young P, Stubby J, Shane E.
    J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
    [Abstract] [Full Text] [Related]

  • 2. Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study.
    Nishiyama KK, Cohen A, Young P, Wang J, Lappe JM, Guo XE, Dempster DW, Recker RR, Shane E.
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2418-25. PubMed ID: 24684466
    [Abstract] [Full Text] [Related]

  • 3. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 4. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
    Cohen A, Kamanda-Kosseh M, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, Bucovsky M, Stubby J, Shane E.
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4208-14. PubMed ID: 26358172
    [Abstract] [Full Text] [Related]

  • 5. Association between P1NP and bone strength in postmenopausal women treated with teriparatide.
    Chen FP, Fu TS, Lin YC, Sung CM, Huang MH, Lin YJ.
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):91-95. PubMed ID: 35181054
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [Abstract] [Full Text] [Related]

  • 7. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [Abstract] [Full Text] [Related]

  • 8. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 9. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
    Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA.
    J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
    [Abstract] [Full Text] [Related]

  • 10. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [Abstract] [Full Text] [Related]

  • 11. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A.
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A.
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [Abstract] [Full Text] [Related]

  • 13. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.
    Cohen A, Shiau S, Nair N, Recker RR, Lappe JM, Dempster DW, Nickolas TL, Zhou H, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Williams JM, McMahon DJ, Stubby J, Shane E.
    J Clin Endocrinol Metab; 2020 Oct 01; 105(10):e3540-56. PubMed ID: 32876328
    [Abstract] [Full Text] [Related]

  • 14. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
    Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M.
    J Bone Miner Res; 2011 Dec 01; 26(12):2823-6. PubMed ID: 21997141
    [Abstract] [Full Text] [Related]

  • 15. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D, Luchavova M, Zikan V, Raska I, Kubena AA, Stepan JJ.
    Osteoporos Int; 2012 Dec 01; 23(12):2885-91. PubMed ID: 22426952
    [Abstract] [Full Text] [Related]

  • 16. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2014 May 01; 99(5):1694-700. PubMed ID: 24517156
    [Abstract] [Full Text] [Related]

  • 17. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
    Finkelstein JS, Wyland JJ, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2010 Apr 01; 95(4):1838-45. PubMed ID: 20164296
    [Abstract] [Full Text] [Related]

  • 18. An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Nakamura T, Kono T, Sudo A.
    Osteoporos Int; 2014 Jan 01; 25(1):377-84. PubMed ID: 23812597
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C.
    Medicine (Baltimore); 2018 Nov 01; 97(47):e13341. PubMed ID: 30461654
    [Abstract] [Full Text] [Related]

  • 20. Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
    Fahrleitner-Pammer A, Burr D, Dobnig H, Stepan JJ, Petto H, Li J, Krege JH, Pavo I.
    Bone; 2016 Aug 01; 89():16-24. PubMed ID: 27185100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.